RNXT RenovoRx, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

RNXT — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
17
List Date
2021-08-26
CIK
0001574094
Last Earnings
Aug 12
Next Earnings
~Nov 12, 2026 (estimated)
Headquarters
Mountain View, CA
Homepage
https://www.renovorx.com

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---32.25%-0.75%-24.24%0.00%24.52%-6.54%
Feb---0.59%65.48%17.01%-27.01%-13.43%8.29%
Mar---11.75%-31.67%-24.72%4.21%14.54%-9.88%
Apr---41.81%0.97%-8.33%0.00%-12.37%-12.31%
May--20.25%-40.38%-4.13%41.40%2.95%4.02%
Jun--2.59%7.11%-1.74%-7.39%6.44%1.40%
Jul---2.78%-13.91%4.35%-2.36%0.45%-2.85%
Aug37.60%7.97%-19.40%-17.07%-20.66%82.08%11.75%
Sep-34.63%-7.34%-21.30%3.92%17.59%-26.07%-11.30%
Oct-12.35%-10.73%3.17%-2.16%-17.16%-14.19%-8.90%
Nov29.67%10.80%-39.62%24.51%-15.83%-9.48%*0.01%
Dec-31.25%25.00%252.31%7.50%-1.96%--50.32%
Total-29.72%-48.69%-13.28%-32.13%-37.97%24.53%-22.88%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.25
SMA 50: $1.53
SMA 200: $1.11
Current: $1.14
EMA 12: $1.25
EMA 26: $1.31
MACD: -0.0611 | Signal: -0.0069
BEARISH
ADX (14): 21.21
WEAK TREND
+DI: 28.01
−DI: 30.15

Momentum Oscillators

RSI (14): 38.11
NEUTRAL
Stoch %K: 31.11
Stoch %D: 32.95
Williams %R: -61.12

Volume & Volatility

BB Upper: $1.46
BB Lower: $1.05
NEUTRAL
OBV: -48,547
Vol SMA 20: 437,817
Vol ROC: 285.27%
ATR: $0.16
True Range: $0.46
HV 20: 82.3%
HV 30: 72.4%
HV 60: 106.5%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis

Click Frenzy-Pro™ for an AI analysis of this ticker.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
All RNXT news →

RNXT Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.4575
Alpha: 34.74%
Correlation: 0.2355
R-Squared: 5.5%
Stock Volatility: 85.3%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own RNXT
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$131K
0.00%
#5674 of 6285-42.6%13F
Renaissance Technologies Hedge fund
Jim Simons
$11K
0.00%
#3123 of 3138-12.3%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

RNXT Institutional Ownership (13F)

Filings for 2026-06-30 · 9 already for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

28 filers9,215,145 shares$11.92M value
# Filer Shares Value % of Total % of Float Period
1 AIGH Capital Management LLC 4,263,622 $6.65M 55.80% — 2026-09-30
2 Bleichroeder LP 1,666,098 $1.63M 13.70% — 2026-06-30
3 Vanguard Capital Management LLC 1,443,742 $1.41M 11.87% — 2026-06-30
4 Geode Capital Management, LLC Custodian 473,093 $738.06K 6.19% — 2026-09-30
5 Wealthspire Advisors, LLC 252,525 $247.47K 2.08% — 2026-06-30
6 Vanguard Fiduciary Trust Co 240,330 $235.52K 1.98% — 2026-06-30
7 T3 Companies, LLC 96,800 $151.01K 1.27% — 2026-09-30
8 Citadel Advisors LLC Custodian 133,597 $130.93K 1.10% — 2026-06-30
9 Chicago Partners Investment Group LLC 92,356 $119.14K 1.00% — 2026-09-30
10 Northern Trust Corp Custodian 85,207 $83.50K 0.70% — 2026-06-30
11 Northwestern Mutual Wealth Management Co 74,596 $73.10K 0.61% — 2026-06-30
12 Caprock Group, LLC 63,940 $62.66K 0.53% — 2026-06-30
13 Kestra Advisory Services, LLC 37,520 $58.53K 0.49% — 2026-09-30
14 Clear Creek Financial Management, LLC 36,706 $57.26K 0.48% — 2026-09-30
15 Jane Street Group, LLC Custodian 46,399 $45.47K 0.38% — 2026-06-30
16 TWO SIGMA SECURITIES, LLC 34,788 $34.09K 0.29% — 2026-06-30
17 XTX Topco Ltd 29,983 $29.38K 0.25% — 2026-06-30
18 State Street Corp 26,152 $25.63K 0.21% — 2026-06-30
19 StoneX Group Inc. 12,578 $22.04K 0.18% — 2026-09-30
20 UBS Group AG Custodian 20,820 $20.40K 0.17% — 2026-06-30
21 HighTower Advisors, LLC 20,000 $19.60K 0.16% — 2026-06-30
22 Cetera Investment Advisers Custodian 19,000 $18.62K 0.16% — 2026-06-30
23 Affinity Capital Advisors, LLC 13,279 $17.00K 0.14% — 2026-09-30
24 CAPTRUST FINANCIAL ADVISORS 12,307 $12.06K 0.10% — 2026-06-30
25 RENAISSANCE TECHNOLOGIES LLC 11,400 $11.17K 0.09% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

RNXT Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 K. Angela Macfarlane Director Grant (A) +55,924 opt — EDGAR
2026-10-02 Una S Ryan Director Grant (A) +55,924 opt — EDGAR
2026-10-02 Laurence Marton Director Grant (A) +55,924 opt — EDGAR
2026-10-02 Robert J. Spiegel Director Grant (A) +55,924 opt — EDGAR
2026-09-15 Mark Voll Chief Financial Officer Award (A) +80,000 — EDGAR
2026-06-24 Una S Ryan Director Other (J) +97,165 $2.85 $276.5K EDGAR
2026-05-21 Mark Voll Chief Financial Officer Buy (P) +25,000 $0.79 $19.7K EDGAR
2026-04-07 Leesa Gentry Chief Clinical Officer Grant (A) +128,550 opt — EDGAR
2026-04-07 Shaun Bagai Chief Executive Officer Grant (A) +946,107 opt — EDGAR
2026-04-07 Ramtin Agah Chief Medical Officer Grant (A) +621,727 opt — EDGAR
2026-04-07 Mark Voll Chief Financial Officer Award (A) +80,000 — EDGAR
2026-03-27 Mark Voll Chief Financial Officer Award (A) +12,380 — EDGAR
2026-03-24 Mark Voll Chief Financial Officer Buy (P) +97,200 — EDGAR
2026-03-24 Laurence Marton Director Buy (P) +9,720 — EDGAR
2026-03-24 Shaun Bagai Chief Executive Officer Buy (P) +24,300 — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

RNXT Insider Holdings

8 insiders · @ $1.14
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Ramtin Agah Chief Medical Officer 1,773,460 $2.02M $171.1K 22 2026-04-07
2 Shaun Bagai Chief Executive Officer 364,340 $415.5K $52.8K 16 2026-04-07
3 Mark Voll Chief Financial Officer 319,580 $364.5K $19.7K 5 2026-09-15
4 Una S Ryan Director 80,959 $92.3K $0 8 2026-10-02
5 Laurence Marton Director 75,884 $86.5K $10.2K 12 2026-10-02
6 Robert J. Spiegel Director 40,983 $46.7K $0 6 2026-10-02
7 K. Angela Macfarlane Director 40,983 $46.7K $0 8 2026-10-02
8 Ron Kocak VP, Controller and PAO 12,595 $14.4K $10.0K 4 2025-07-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

RNXT Board & Officers

As of SEC filings through Oct 2, 2026

Directors 6

Officers 5

  • Shaun Bagai · Chief Executive Officer · since Aug 25, 2021
  • Mark Voll · Chief Financial Officer · since Feb 4, 2026
  • Ramtin Agah · Chief Medical Officer · since Aug 25, 2021
  • Leesa Gentry · Chief Clinical Officer · since Mar 1, 2024
  • Ron Kocak · VP, Controller and PAO · since Feb 9, 2024
Changes in the last 10 years (25)
Feb 4, 2026Mark Voll became Chief Financial Officer
Mar 1, 2024Leesa Gentry became Chief Clinical Officer
Feb 16, 2024The company announced the departure of Angela Nelms as Chief Operating Officer in an SEC filing
Feb 9, 2024Ron Kocak became VP, Controller and PAO
Apr 25, 2023Robert J. Spiegel became a director
Mar 29, 2023Ramtin Agah no longer listed as a 10% owner in SEC filings
Sep 19, 2022Angela Nelms became Chief Operating Officer
Jul 15, 2022James M Ahlers became Chief Financial Officer
Jul 13, 2022The company announced the departure of Christopher John Lehman as Chief Financial Officer in an SEC filing
Jun 9, 2022Ramtin Agah first listed as a 10% owner in an SEC filing
Mar 16, 2022Bank of the West became a 10% owner
Oct 4, 2021Ramtin Agah no longer listed as a 10% owner in SEC filings
Aug 30, 2021Christopher John Lehman became Chief Financial Officer
Aug 25, 2021Una S Ryan became a director
Aug 25, 2021Shaun Bagai became a director
Aug 25, 2021Shaun Bagai became Chief Executive Officer
Aug 25, 2021Ramtin Agah became a director
Aug 25, 2021Ramtin Agah became a 10% owner
Aug 25, 2021Ramtin Agah became Chief Medical Officer
Aug 25, 2021Paul Manners became Chief Financial Officer
Not reported recently (6)
  • David Diamond · Last reported as a director in an SEC filing dated Oct 2, 2023
  • James M Ahlers · Last reported as Chief Financial Officer in an SEC filing dated Jul 20, 2022
  • Bank of the West · Last reported as a 10% owner in an SEC filing dated Apr 14, 2022
  • Kamran Najmabadi · Last reported as a 10% owner in an SEC filing dated Aug 25, 2021
  • Najmabadi Family Trust dated April 22, 2021 · Last reported as a 10% owner in an SEC filing dated Aug 25, 2021
  • Paul Manners · Last reported as Chief Financial Officer in an SEC filing dated Aug 25, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-11-05 Earnings results EDGAR
2026-08-20 Other events EDGAR
2026-08-12 Financial statements and exhibits EDGAR
2026-08-04 Other events EDGAR
2026-07-02 Listing standards notice EDGAR
2026-06-30 Shareholder vote results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-11-05 0001193125-26-449910 EDGAR
2026-08-13 0001193125-26-349190 EDGAR
ETF Holders
2 ETFs hold RNXT
2 shown · $2.56M total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $1.8M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $709,081 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

RNXT vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
SYK Stryker Corporation $124.1B 34.7 +7.9% −6.3% 30
MMM 3M Company $95.5B 28.4 +1.7% +17.7% 23
BSX Boston Scientific Corp. $62.0B 18.7 +8.9% −53.3% 21
BDX Becton, Dickinson and Co. $57.7B 54.7 +6.4% +10.9% 29
MDLN Medline Inc. Class A common stock $34.8B 0.0 — +1.3% 5
RMD ResMed Inc. $33.1B 21.6 +9.0% −3.3% 22
DXCM DexCom, Inc. $29.6B 31.9 +13.0% +21.7% 44
WST West Pharmaceutical Services, Inc. $27.9B 46.2 +12.6% +48.8% 17
RNXT RenovoRx, Inc. Common Stock $51M — — +36.6% —
Peer median $46.3B 30.1 +8.9% +6.1% 23

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.